PH12022550146A1 - Tumour infiltrating lymphocyte therapy and uses thereof - Google Patents

Tumour infiltrating lymphocyte therapy and uses thereof

Info

Publication number
PH12022550146A1
PH12022550146A1 PH1/2022/550146A PH12022550146A PH12022550146A1 PH 12022550146 A1 PH12022550146 A1 PH 12022550146A1 PH 12022550146 A PH12022550146 A PH 12022550146A PH 12022550146 A1 PH12022550146 A1 PH 12022550146A1
Authority
PH
Philippines
Prior art keywords
patients
expression
biomarker
therapy
receptor
Prior art date
Application number
PH1/2022/550146A
Other languages
English (en)
Inventor
John Stephen Bridgeman
Nicola Kaye Price
Original Assignee
Instil Bio Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instil Bio Uk Ltd filed Critical Instil Bio Uk Ltd
Publication of PH12022550146A1 publication Critical patent/PH12022550146A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
PH1/2022/550146A 2019-07-24 2020-07-24 Tumour infiltrating lymphocyte therapy and uses thereof PH12022550146A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962878001P 2019-07-24 2019-07-24
GBGB1910605.3A GB201910605D0 (en) 2019-07-24 2019-07-24 Tumour infltracting lymphocyte therapy amd uses thereo
PCT/GB2020/051790 WO2021014174A1 (en) 2019-07-24 2020-07-24 Tumour infiltrating lymphocyte therapy and uses thereof

Publications (1)

Publication Number Publication Date
PH12022550146A1 true PH12022550146A1 (en) 2023-12-04

Family

ID=67839864

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/550146A PH12022550146A1 (en) 2019-07-24 2020-07-24 Tumour infiltrating lymphocyte therapy and uses thereof

Country Status (18)

Country Link
US (1) US20220378826A1 (cg-RX-API-DMAC7.html)
EP (1) EP4003372A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022541523A (cg-RX-API-DMAC7.html)
KR (1) KR20220041839A (cg-RX-API-DMAC7.html)
CN (1) CN114174495A (cg-RX-API-DMAC7.html)
AU (1) AU2020316708A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022001139A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142913A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000152A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021018066A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220027A (cg-RX-API-DMAC7.html)
EC (1) ECSP22004616A (cg-RX-API-DMAC7.html)
GB (1) GB201910605D0 (cg-RX-API-DMAC7.html)
IL (1) IL289235A (cg-RX-API-DMAC7.html)
MX (1) MX2022000439A (cg-RX-API-DMAC7.html)
PE (1) PE20220258A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550146A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021014174A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
CN109536444B (zh) * 2018-12-11 2022-06-28 吉林省拓华生物科技有限公司 一种适用于恶性实体瘤肿瘤浸润t淋巴细胞的分离诱导方法
GB201900858D0 (en) * 2019-01-22 2019-03-13 Price Nicola Kaye Receptors providing targeted costimulation for adoptive cell therapy
JP2023507432A (ja) 2019-12-20 2023-02-22 インスティル バイオ (ユーケイ) リミテッド 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用
WO2021222479A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
KR20230159840A (ko) * 2021-03-23 2023-11-22 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 항원 반응성 t 세포 수용체
WO2022271881A1 (en) * 2021-06-24 2022-12-29 Instil Bio, Inc. Methods of isolating of tumor infiltrating lymphocytes and use thereof
CN119643843B (zh) * 2022-03-15 2025-08-12 上海君赛生物科技有限公司 肿瘤特异性免疫细胞标志物及其用途
JP2024012879A (ja) * 2022-07-19 2024-01-31 国立大学法人三重大学 腫瘍反応性t細胞の製造方法
CN116162653A (zh) * 2023-03-30 2023-05-26 湖北省农业科学院畜牧兽医研究所 靶向切除猪SlamF1基因编码区DNA的成对编辑位点、使用方法及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1867720A3 (en) * 1994-12-02 2008-01-09 Schering Corporation Purified genes encoding mammalian cell surface antigens; proteins and antibodies
WO2002062999A2 (en) * 2000-12-29 2002-08-15 Curagen Corporation Proteins and nucleic acids encoding same
EP2336167B1 (en) * 2001-03-14 2019-05-29 Dako Denmark A/S MHC molecule constructs and their uses for diagnosis and therapy
MXPA05000655A (es) * 2002-07-15 2006-02-22 Harvard College Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
ES2749862T3 (es) * 2014-01-27 2020-03-24 Molecular Templates Inc Polipéptidos efectores desinmunizados de subunidad A de toxina Shiga para aplicaciones en mamíferos
CN106459991B (zh) * 2014-04-07 2021-03-05 洛孔法尔马有限公司 新型药剂及其用途
WO2017179015A1 (en) * 2016-04-15 2017-10-19 Glaxosmithkline Intellectual Property Development Limited Compositions for the treatment of cancer
AU2018301668A1 (en) * 2017-07-12 2019-12-19 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
GB201801067D0 (en) * 2018-01-23 2018-03-07 Price Nicola Kaye Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof
CN113899903B (zh) * 2020-07-06 2025-08-29 上海市免疫学研究所 结直肠癌生物标志物及其在诊断、预防、治疗及预后中的应用
CN116769729B (zh) * 2023-06-05 2024-07-02 中国科学技术大学 靶向cd150的抗体或抗原结合片段及其应用

Also Published As

Publication number Publication date
US20220378826A1 (en) 2022-12-01
GB201910605D0 (en) 2019-09-04
MX2022000439A (es) 2022-08-15
IL289235A (en) 2022-02-01
CA3142913A1 (en) 2021-01-28
ECSP22004616A (es) 2022-02-25
JP2022541523A (ja) 2022-09-26
CR20220027A (es) 2022-02-25
AU2020316708A1 (en) 2022-03-03
CL2022000152A1 (es) 2022-10-07
WO2021014174A1 (en) 2021-01-28
EP4003372A1 (en) 2022-06-01
PE20220258A1 (es) 2022-02-21
BR112022001139A2 (pt) 2022-03-15
CN114174495A (zh) 2022-03-11
KR20220041839A (ko) 2022-04-01
CO2021018066A2 (es) 2022-02-07

Similar Documents

Publication Publication Date Title
PH12020551110A1 (en) Biomarker predictive of tumour infiltrating lymphocyte therapy and uses thereof
MX2022000439A (es) Terapia con linfocitos de infiltracion tumoral y sus usos.
Kaur et al. Natural killer cells target and differentiate cancer stem-like cells/undifferentiated tumors: strategies to optimize their growth and expansion for effective cancer immunotherapy
WO2020227159A3 (en) Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
Sauter et al. A phase 1 study of NKX101, a chimeric antigen receptor natural killer (CAR-NK) cell therapy, with fludarabine and cytarabine in patients with acute myeloid leukemia
Brudno et al. T cells expressing a novel fully-human anti-CD19 chimeric antigen receptor induce remissions of advanced lymphoma in a first-in-humans clinical trial
MY209449A (en) Anti-cd19 therapy in patients having a limited number of nk cells
ZA202100296B (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
NZ601943A (en) Antibodies against cxcr4
Beider et al. Upregulation of senescent/exhausted phenotype of CAR T cells and induction of both treg and myeloid suppressive cells correlate with reduced response to CAR T cell therapy in relapsed/refractory B cell malignancies
NZ602515A (en) Proteins that bind pi16 and uses thereof
MX2018011169A (es) Metodo para prevenir la enfermedad del injerto contra huesped.
Komrokji et al. Azacitidine treatment for lenalidomide (LEN)-resistant myelodysplastic syndrome (MDS) with del 5q
MX2021010274A (es) Celulas, composiciones y metodos para mejorar la funcion inmune.
Borg et al. Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma
Lemoli et al. Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with acute myeloblastic leukemia
Tsirigotis et al. Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine
Chin et al. A safe and simple approach to obtaining sufficient cytokine induced killer (CIK) cells from critically-ill cancer patients without the need for apheresis or peripheral mobilization
Heinicke et al. Comparison of Outcome after Allogeneic Stem Cell Transplantation in AML Patients in First or Second Complete Remission Following Either Fludarabin/Busulfan, Flamsa-TBI or Flamsa-Bu Conditioning
Valés-Gómez Bacillus Calmette Guérin in bladder cancer: is more immune stimulation better?
Trilla et al. Cost analysis of cardiac transplantation in a Spanish hospital
Fioranelli et al. Theoretical-Scientific Foundations about the Use of Low-Dose in Oncology
Tarke et al. T cell activation by OKT3 is a function of the percent monocytes in PBMC of healthy donors and MDS patients
Hoffmann et al. Marked Impact of Different Cytokines on Phenotype and Cytotoxic Activity of CD19-Specific CAR T Cells
Orfali et al. Haplo-Cord Transplantation with Anti-Thymocyte Globulin: Comparative Clinical Outcomes with or without Routine G-CSF Administration